## SYNOCURE® 857 X 60

**GENERAL INDUSTRY** 

**ARKEMA COATING RESINS** 

Product Application details	SYNOCURE <sup>®</sup> 857 X 60 is a hydroxy functional acrylic resin designed to crosslink at room temperature with polyisocyanates, and is particularly recommended where economy in use is a major factor.			
Performance Benefits	<ul> <li>Excellent flexibility</li> <li>Exceptionally fast drying</li> <li>High gloss</li> <li>Low isocyanate requirement</li> <li>Good hardening rate</li> </ul>			
Polymer Type	Solventborne Acrylic			
Sales Specifications	Solid Content at 125°C, % (ISO 325	51)		58 - 62
	Viscosity at 25°C, mPa.s (ISO 12058-1)			1000 - 2500
	Colour, Pt/Co Scale (DIN EN 1557)			70 max
	Acid value, mg KOH/g (ISO 2114)			10 max
	Volatile			Xylene
	Flash point, °C (ISO 3679)			24
Other	Density / Specific Gravity at 20°C, g/ml (ISO 2811)			1.03
Other Characteristics <sup>1</sup>	Hydroxyl Content, %			1.2
Characteristics	, , , , , , , , , , , , , , , , , , , ,			1400
	Note: Acid value and/or Hydroxyl value quoted relative to solid resin 1 The data provided for these properties are typical values, intended only as guides, and should not be construed as sales specifications			
Formulation Guidelines	RECOMMENDATIONS FOR USE SYNOCURE® 857 X 60 should be mi The mixing ratio is not critical altroptimum performance. The reaction ratio is calculated from content of the reactants. The relation Hydroxyl equivalent weight = $\frac{17 \times 10}{\% \text{ OF}}$ Isocyanate equivalent weight = $42 \times 100000000000000000000000000000000000$	hough it is preferal the respective equiparts is:	ble to use stoichiom	etric ratios to obtain
	SYNOCURE <sup>®</sup> 857 X 60 reacted with stoichiometric proportions has a us day at normal room temperature.	able pot life at spra	aying viscosity in exe	cess of a full working

storage period.



	To increase the initial rate of cure of SYNOCURE <sup>®</sup> 857 X 60 paints, at both room temperature and under low bake conditions, the use of tin or zinc catalysts in the form of dibutyl tin dilaurate or zinc octoate is recommended. The levels used will depend on specific requirements, but typical metal contents calculated on total solid resin would be 0.001% tin or 0.0015% zinc. Paints prepared using stoichiometric blends of SYNOCURE <sup>®</sup> 857 X 60 and Desmodur <sup>®</sup> N 75 series (1) or Tolonate <sup>™</sup> HDB 75 MX (2) give coatings which are sand dry in 7min - 10 min and hard dry in about 40 min at normal room temperature.
	<u>SOLUBILITY</u> The solvents chosen for paints and lacquers based on SYNOCURE <sup>®</sup> 857 X 60 should be free of water and should not contain groups that react with isocyanates. Esters and ketones are true solvents for this type of system and are recommended for use in conjunction with aromatic hydrocarbon diluents such as xylene.
	Notes: (1) Bayer MaterialScience, (2)Vencorex Chemicals
Product Safety	Please refer to the corresponding Safety Data Sheet.
Storage & Handling	SYNOCURE <sup>®</sup> 857 X 60 should be stored indoors in the original, unopened and undamaged container, in a dry place at a temperature not exceeding 30°C. Exposure to direct sunlight should be avoided. In the above mentioned storage conditions the shelf life of the resin will be 12 months from the shipping date

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations.

Arkema has implemented a Medical Policy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/responsible-product-management/medical-device-policy/index.html) Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices.

It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician.

Arkema Coating Resins

420, rue d'Estienne d'Orves

92705 Colombes Cedex - France arkema.com - arkemacoatingresins.com



with the Commercial and Companies Register of Nanterre (France) under number 319 632 790

registered

anonyme"

Arkema Fri - 07/2022